Merck & Co Could Be Plotting $30bn Bid For Seagen
Regulatory Concerns Remain
Executive Summary
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
You may also be interested in...
Seagen, With Two Big Pharma Bidders, Nearly Lost Both
Seagen was being pursued by another prospective big pharma buyer when it engaged Pfizer in merger negotiations, but both bidders walked away in late summer 2022; Pfizer returned in January.
IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.